Congestive heart failure after anthracycline‐containing treatment for Hodgkin lymphoma: A Swedish matched cohort study
These findings highlight that cHL survivors still face a substantial excess risk of CHF in the modern treatment era and that focus on cardiovascular health remains relevant.
Authors
- Joachim Bæch (ORCID: https://orcid.org/0000-0001-8848-4879)
- Tarec Christoffer El‐Galaly (ORCID: https://orcid.org/0000-0002-4406-380X)
- Joshua P. Entrop (ORCID: https://orcid.org/0000-0003-1614-8096)
- Ingrid Cecilia Glimelius (ORCID: https://orcid.org/0000-0001-6158-3041)
- Sandra Eloranta (ORCID: https://orcid.org/0000-0001-5806-0573)
- Caroline E. Dietrich (ORCID: https://orcid.org/0000-0001-8231-8183)
- Michael J. Crowther (ORCID: https://orcid.org/0000-0001-8378-8259)
- Sissel J Godtfredsen (ORCID: https://orcid.org/0000-0002-1049-9285)
- Karin E. Smedby (ORCID: https://orcid.org/0000-0002-2104-3320)
- Daniël G. M. Molin (ORCID: https://orcid.org/0000-0002-9646-7283)
Institutions
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- Aarhus University Hospital (DK)
- Karolinska Institutet (SE)
Publication Details
- Journal
- eJHaem
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1002/jha2.1048
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.80